Skip to main content
Top
Published in: Journal of Neurology 12/2012

01-12-2012 | Original Communication

The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life

Authors: Angelo Antonini, Paolo Barone, Roberto Marconi, Letterio Morgante, Salvatore Zappulla, Francesco Ernesto Pontieri, Silvia Ramat, Maria Gabriella Ceravolo, Giuseppe Meco, Giulio Cicarelli, Massimo Pederzoli, Michela Manfredi, Roberto Ceravolo, Marco Mucchiut, Giampiero Volpe, Giovanni Abbruzzese, Edo Bottacchi, Luigi Bartolomei, Giuseppe Ciacci, Antonino Cannas, Maria Giovanna Randisi, Alfredo Petrone, Mario Baratti, Vincenzo Toni, Giovanni Cossu, Paolo Del Dotto, Anna Rita Bentivoglio, Michele Abrignani, Rossana Scala, Franco Pennisi, Rocco Quatrale, Rosa Maria Gaglio, Alessandra Nicoletti, Michele Perini, Tania Avarello, Antonio Pisani, Augusto Scaglioni, Paolo Emilio Martinelli, Francesco Iemolo, Laura Ferigo, Pasqualino Simone, Paola Soliveri, Biagio Troianiello, Domenico Consoli, Alessandro Mauro, Leonardo Lopiano, Giuseppe Nastasi, Carlo Colosimo

Published in: Journal of Neurology | Issue 12/2012

Login to get access

Abstract

Non-motor symptoms are gaining relevance in Parkinson’s disease (PD) management but little is known about their progression and contribution to deterioration of quality of life. We followed prospectively 707 PD patients (62 % males) for 2 years. We assessed non-motor symptoms referred to 12 different domains, each including 1–10 specific symptoms, as well as motor state (UPDRS), general cognition, and life quality. Hoehn & Yahr (H&Y) stage was used to categorize patient status (I–II mild; III moderate; IV–V severe). We found that individual non-motor symptoms had variable evolution over the 2-year follow-up with sleep, gastrointestinal, attention/memory and skin disturbances (hyperhidrosis and seborrhea) becoming more prevalent and psychiatric, cardiovascular, and respiratory disorders becoming less prevalent. Development of symptoms in the cardiovascular, apathy, urinary, psychiatric, and fatigue domains was associated with significant life-quality worsening (p < 0.0045, alpha with Bonferroni correction). During the observation period, 123 patients (17 %) worsened clinically while 584 were rated as stable. There was a fivefold greater increase in UPDRS motor score in worse compared with stable patients over 24 months (p < 0.0001 vs. baseline both in stable and worse group). The total number of reported non-motor symptoms increased over 24 months in patients with motor worsening compared to stable ones (p < 0.001). Thirty-nine patients died (3.4 % of patients evaluable at baseline) with mean age at death of 74 years. Deceased patients were older, had significantly higher H&Y stage and motor score, and reported a greater number of non-motor symptoms at baseline. In conclusion, overall non-motor symptom progression does not follow motor deterioration, is symptom-specific, and only development of specific domains negatively impacts quality of life. These results have consequences for drug studies targeting non-motor features.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef
2.
go back to reference Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Macphee G et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629PubMedCrossRef Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Macphee G et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629PubMedCrossRef
3.
go back to reference Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMedCrossRef Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMedCrossRef
4.
go back to reference Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef
5.
go back to reference Simuni T, Sethi K (2008) Non-motor manifestations of Parkinson’s disease. Ann Neurol 64(Suppl 2):S65–S80PubMed Simuni T, Sethi K (2008) Non-motor manifestations of Parkinson’s disease. Ann Neurol 64(Suppl 2):S65–S80PubMed
6.
go back to reference Beiske AG, Loge JH, Rønningen A, Svensson E (2009) Pain in Parkinson’s disease: prevalence and characteristics. Pain 141:173–177PubMedCrossRef Beiske AG, Loge JH, Rønningen A, Svensson E (2009) Pain in Parkinson’s disease: prevalence and characteristics. Pain 141:173–177PubMedCrossRef
7.
go back to reference Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474PubMedCrossRef Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474PubMedCrossRef
8.
go back to reference Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580PubMedCrossRef Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580PubMedCrossRef
9.
go back to reference Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 20:190–199PubMedCrossRef Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 20:190–199PubMedCrossRef
10.
go back to reference Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022PubMedCrossRef Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022PubMedCrossRef
11.
go back to reference Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474PubMedCrossRef Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474PubMedCrossRef
12.
go back to reference Antonini A, Colosimo C, Marconi R, Morgante L, Barone P (2008) The PRIAMO Study: background, methods and recruitment. Neurol Sci 29:61–65PubMedCrossRef Antonini A, Colosimo C, Marconi R, Morgante L, Barone P (2008) The PRIAMO Study: background, methods and recruitment. Neurol Sci 29:61–65PubMedCrossRef
13.
14.
go back to reference Fahn S, Elton R, Members of the UPDRS Development Committee (1987) The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–63, 293–304 Fahn S, Elton R, Members of the UPDRS Development Committee (1987) The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–63, 293–304
15.
go back to reference Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
16.
go back to reference Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55:1621–1626PubMedCrossRef Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55:1621–1626PubMedCrossRef
17.
go back to reference Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248PubMedCrossRef Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248PubMedCrossRef
18.
19.
go back to reference McDowell I, Newell C (1996) Measuring health: a guide to rating scales and questionnaires. Oxford University Press, New York McDowell I, Newell C (1996) Measuring health: a guide to rating scales and questionnaires. Oxford University Press, New York
20.
go back to reference Measso GF, Cavarzeran F, Zappalà G, Lebowitz BD, Pirozzolo FJ, Amaducci LA et al (1993) The Mini-Mental State Examination: normative study of a random sample of Italian population. Dev Neuropsychol 9:77–85CrossRef Measso GF, Cavarzeran F, Zappalà G, Lebowitz BD, Pirozzolo FJ, Amaducci LA et al (1993) The Mini-Mental State Examination: normative study of a random sample of Italian population. Dev Neuropsychol 9:77–85CrossRef
21.
go back to reference Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116PubMedCrossRef Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116PubMedCrossRef
22.
go back to reference Istituto Nazionale di Statistica (2008) Tavole di mortalità della popolazione residente Istituto Nazionale di Statistica (2008) Tavole di mortalità della popolazione residente
23.
go back to reference Poewe W, Mahlknecht P (2009) The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 15:S28–S32PubMedCrossRef Poewe W, Mahlknecht P (2009) The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 15:S28–S32PubMedCrossRef
24.
go back to reference Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22:938–945PubMedCrossRef Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22:938–945PubMedCrossRef
25.
go back to reference Maetzler W, Liepelt I, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8:1158–1171PubMedCrossRef Maetzler W, Liepelt I, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8:1158–1171PubMedCrossRef
26.
go back to reference Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S et al (2010) The non-declaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:697–701CrossRef Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S et al (2010) The non-declaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:697–701CrossRef
27.
go back to reference Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRef Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRef
28.
go back to reference Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73(21):1738–1745PubMedCrossRef Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73(21):1738–1745PubMedCrossRef
Metadata
Title
The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life
Authors
Angelo Antonini
Paolo Barone
Roberto Marconi
Letterio Morgante
Salvatore Zappulla
Francesco Ernesto Pontieri
Silvia Ramat
Maria Gabriella Ceravolo
Giuseppe Meco
Giulio Cicarelli
Massimo Pederzoli
Michela Manfredi
Roberto Ceravolo
Marco Mucchiut
Giampiero Volpe
Giovanni Abbruzzese
Edo Bottacchi
Luigi Bartolomei
Giuseppe Ciacci
Antonino Cannas
Maria Giovanna Randisi
Alfredo Petrone
Mario Baratti
Vincenzo Toni
Giovanni Cossu
Paolo Del Dotto
Anna Rita Bentivoglio
Michele Abrignani
Rossana Scala
Franco Pennisi
Rocco Quatrale
Rosa Maria Gaglio
Alessandra Nicoletti
Michele Perini
Tania Avarello
Antonio Pisani
Augusto Scaglioni
Paolo Emilio Martinelli
Francesco Iemolo
Laura Ferigo
Pasqualino Simone
Paola Soliveri
Biagio Troianiello
Domenico Consoli
Alessandro Mauro
Leonardo Lopiano
Giuseppe Nastasi
Carlo Colosimo
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 12/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6557-8

Other articles of this Issue 12/2012

Journal of Neurology 12/2012 Go to the issue